BRIEF-Dynavax presents pivotal phase 3 data showing HEPLISAV-B provides significantly higher protection against Hepatitis B than ENGERIX-B(R)
April 18, 2016 at 16:43 PM EDT
* Dynavax presents pivotal phase 3 data showing heplisav-b(tm) provides significantly higher protection against hepatitis b than engerix-b(r)
